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ABSTRACT
Objective To determine whether self monitoring, alone or
with instruction in incorporating the results into self care,
is more effective than usual care in improving glycaemic
control in non-insulin treated patients with type 2
diabetes.
Design Three arm, open, parallel group randomised trial.
Setting 48 general practices in Oxfordshire and South
Yorkshire.
Participants 453 patients with non-insulin treated type 2
diabetes (mean age 65.7 years) for a median duration of
three years and a mean haemoglobin A1c level of 7.5%.
Interventions Standardised usual care with
measurements of HbA1c every threemonths as the control
group (n=152), blood glucose self monitoring with advice
for patients to contact their doctor for interpretation of
results, in addition to usual care (n=150), and blood
glucose self monitoring with additional training of
patients in interpretation and application of the results to
enhance motivation and maintain adherence to a healthy
lifestyle (n=151).
Main outcome measure HbA1c level measured at
12 months.
Results At 12 months the differences in HbA1c level
between the three groups (adjusted for baseline HbA1c
level) were not statistically significant (P=0.12). The
difference in unadjustedmean change in HbA1c level from
baseline to 12 months between the control and less
intensive self monitoring groups was −0.14% (95%
confidence interval −0.35% to 0.07%) and between the
control and more intensive self monitoring groups was
−0.17% (−0.37% to 0.03%).
Conclusions Evidence is not convincing of an effect of self
monitoring blood glucose, with or without instruction in
incorporating findings into self care, in improving
glycaemic control comparedwith usual care in reasonably
well controlled non-insulin treated patients with type 2
diabetes.
Trial registration Current Controlled Trials
ISRCTN47464659.
INTRODUCTION
As the number of people diagnosed as having type 2
diabetes continues to rise1 so does the challenge of
monitoring andmanaging the condition. Self monitor-
ing of blood glucose for people with non-insulin trea-
ted diabetes may lead to improved glycaemic control
and is commonly recommended. Existing evidence of
effectiveness is, however, inconclusive.2-4 Despite lim-
itations in trial evidence, proponents of selfmonitoring
of blood glucose cite the benefits reported in some
observational studies of patients with diabetes,5 6 but
these analyses may not have fully adjusted for the
potential confounding effect of an association between
self monitoring of blood glucose and take-up of other
health improving behaviours. Meanwhile the use of
self monitoring in this group of patients and the cost
to health systems of the consumable test strips have
become a major and increasing proportion of health-
care budgets.7 8
We tested whether self monitoring of blood glucose,
with or without instruction in incorporating findings
into self care, compared with standardised usual care
can improve glycaemic control in patients with non-
insulin treated diabetes.
METHODS
The diabetes glycaemic education and monitoring
(DiGEM) study was a four year open, randomised,
three arm, parallel group trial with sequential recruit-
ment of patients from general practices in Oxfordshire
and South Yorkshire. The trial was managed from the
coordinating centre at the Department of Primary
Health Care, University of Oxford.9
Our primary aim was to determine whether haemo-
globin A1c (HbA1c) levels at 12 months were signifi-
cantly different between patients with non-insulin
treated type 2 diabetes receiving one of three allocated
interventions: standardised usual care with measure-
ments of HbA1c levels by health professionals every
three months (control group); use of a blood glucose
meter, with advice for participants to contact their doc-
tor for interpretation of results (less intensive self mon-
itoring); and use of a blood glucosemeter with training
in self interpretation and application of the results to
diet, physical activity, and drug adherence (more
intensive self monitoring).
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Patients were eligible for randomisation if they had
type 2 diabetes, were aged 25 years or more at diagno-
sis, were managed with diet or oral hypoglycaemic
agents alone, had an HbA1c level ≥6.2% at the assess-
ment visit, and were independent in activities of daily
living. Exclusion criteria were the use of a blood glu-
cose monitor twice a week or more often over the pre-
vious three months, serious disease or limited life
expectancy that would make intensive glycaemic con-
trol inappropriate, or inability to follow trial proce-
dures.
Outcome measures
The primary outcome was the HbA1c level at
12 months. Secondary outcomes were blood pressure,
weight, total cholesterol level, ratio of total cholesterol
to high density lipoprotein cholesterol, and bodymass
index. HbA1c was measured using a Variant II Hemo-
globin Testing System (Bio-Rad Laboratories, Her-
cules, CA) certified by the US glycohaemoglobin
standardisation programme and comparable to the
diabetes control and complications trial standard,
with an interassay coefficient of variation across the
range of the assay of less than 2%. Cholesterol was
assayed in local laboratories and the results aligned
with results of a sample of paired specimens analysed
with an automated chemistry analyser (Olympus
AU400;Olympus, Tokyo), with interassay coefficients
of variation across the range of less than 2%. Blood
pressure was measured twice in the right arm, with
the participant seated, using a UA-779 electronic
blood pressure monitor (A&D instruments, Abing-
don), and the mean of these values was analysed.
We transcribed the frequency of blood glucose test-
ing from patient held diaries. Episodes of hypoglycae-
mia were categorised as grade 2 (mild symptoms
requiring minor intervention), grade 3 (moderate
symptoms requiring immediate third party inter-
vention), or grade 4 (unconscious). Increases in hypo-
glycaemicdrugsweredefined as an increase in thedose
or frequency prescribed, progression from use of a sin-
gle oral agent to combination oral therapy, or addition
of insulin to the treatment regimen.
To characterise the groups and identify subgroups
for predefined analysis at 12months we collected addi-
tional personal and clinical data on duration of dia-
betes, drug treatment, diabetes related complications,
and EuroQol (EQ-5D) score.10
Randomisation
We used computerised randomisation (Minim, www.
sghms.ac.uk/depts/phs/guide/randser.htm) incorpor-
ating a partial minimisation procedure to adjust the
randomisation probabilities between groups to bal-
ance three important covariates collected at baseline:
duration of diabetes, HbA1c level, and current treat-
ment (diet, oral monotherapy, or oral combination
therapy). The minimisation procedure to assign
patients to their allocated intervention was conducted
independently of the research nurses who managed
recruitment and carried out the assessment visit. The
allocation was also concealed from laboratory staff.
Procedures
We identified patients suitable for trial inclusion from
lists held on computer by their general practitioners.
Those eligible were sent an invitation to participate
signed by their general practitioner accompanied by
an information sheet and a reply paid envelope. One
further letter was sent if no response was received
within one month.
Eligibility for the trial and willingness to be rando-
mised to self testing of blood glucosewas confirmed by
a preassessment phone call and at the visit for assess-
ment. At the assessment visit, after obtaining informed
consent, beliefs about diabetes were elicited using a
standard approach to help patients understand how
diabetes might present a threat to their health.11 The
roles of diet, physical activity, and drugs were dis-
cussed within the framework of the commonsense
model of illness representation,11 in which we set out
to optimise the use of feedback on glucose levels to
Total list (n=364 527)
People with diabetes (n=9881)
No diabetes (n=354 646)
Type 2 diabetes (n=8457)
Type 1 diabetes (n=1424)
Positive response (n=955, 32%)
No response (n=2031)
Total eligible (n=2986)
Ineligible
Meter use (n=1616, 30%)
Other (n=3855, 70%)
Eligible for assessment (n=578)
Ineligible
Meter use (n=211, 56%)
Other (n=166, 44%)
Randomised (n=453)
Control
(n=152)
Died (n=1)
Lost to follow-up (n=17)
Less intensive self
monitoring (n=150)
More intensive self
monitoring (n=151)
Included in intention to
treat analysis (n=152)
Included in intention to
treat analysis (n=150)
Included in intention to
treat analysis (n=151)
Ineligible
Meter use (n=2, 2%)
Haemoglobin A1c <6.2% (n=93, 74%)
Other (n=30, 24%)
Started to
monitor (n=8)
Died (n=3)
Lost to follow-up (n=11)
Did not persist
monitoring (n=51)
Died (n=4)
Lost to follow-up (n=21)
Did not persist
monitoring (n=72)
Fig 1 | Trial profile
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facilitate behaviour change through influencing
beliefs. The behaviour change techniques were
selected on the basis of evidence for effectiveness and
included goal setting and review of physical activity
and eating patterns to help patients with lifestyle
change.12 13 The goal setting and review approach was
continued in subsequent visits. Baselineblood tests and
clinical measurements were taken and questionnaires
completed at the assessment visit.
Interventions
After the assessment visit and confirmation of eligibil-
ity, patients were allocated to receive one of the three
interventions. The rationale behind these inter-
ventions is described in more detail elsewhere.9 The
intervention was initiated at the first visit after rando-
misation and continued at the scheduled visits at one,
three, six, and nine months. Each of the three inter-
ventions included a series of standardised components.
Patients allocated to the control intervention
received standardised usual care, including the use of
goal setting and review. They were asked not to use a
blood glucose meter unless their doctor considered it
essential for their clinical management. A diary was
used to record self care goals and strategies for achiev-
ing them.
Patients allocated to the less intensive self monitor-
ing intervention continued to use the goal setting and
review techniques introduced at the assessment visit.
In addition they were given a blood glucose meter.
They were asked to record three values daily on two
days during the week (one after fasting and the other
two before meals or two hours after meals) and to aim
for glucose levels of 4-6mmol/l after fasting and before
meals and levels of 6-8 mmol/l two hours after meals.
They were advised by the nurse to consider contacting
their doctor if readings were consistently high
(>15 mmol/l) or low (<4 mmol/l). They were not
given information about how to interpret their blood
glucose readings. Separate diaries were used to record
identified goals and activity and to record blood glu-
cose results.
Patients allocated to the more intensive intervention
continued to use goal setting and review and were also
given a blood glucose meter. They were also given
training and support in timing, interpreting, and
using the results of their blood glucose test to enhance
motivation and tomaintain adherence to diet, physical
activity, and drug regimens. They were encouraged to
experiment with monitoring to explore the effect of
specific activities, such as exercise, on their blood glu-
cose level and to reflect on abnormal values in an
attempt to identify what might have contributed to
them. A single diary was used to record goals, activ-
ities, and blood glucose results.
Follow-up visits differed in content according to the
allocated intervention in line with usual practice.
Patients allocated to the control intervention had a
blood test to measure HbA1c level two weeks before
their scheduled visit, the result of which was fed back
to them as an indication of the impact of their self care
activities on their glycaemic control. Blood glucose
values were reviewed at the scheduled visit for those
allocated to self monitoring, and patients were told to
seek advice from their doctor if fasting valueswere per-
sistently greater than 6mmol/l. Patients in each arm of
the trial received feedback on glycaemic control,
which was used to explore success of goals and to set
new ones. The patient’s doctor was notified of all
HbA1c results and asked to consider changes in drugs
in line with the National Institute for Clinical Excel-
lence diabetes guidelines for all patients.14 The doctor
was also notified if blood glucose readings were consis-
tently greater than 15 mmol/l.
The meters were calibrated to provide plasma
equivalent results (Optium, Abbott Diabetes Care,
Maidenhead, UK). Calibration of the meters was
Table 1 | Personal and baseline characteristics of patientswith non-insulin treated type 2
diabetesbefore intervention,by randomisationgroup.Valuesarenumbers (percentages) unless
stated otherwise
Variables
Control group*
(n=152)
Meter group; less
intensive self
monitoring (n=150)
Meter group; more
intensive self
monitoring (n=151)
Personal characteristics
Mean (SD) age (years) 66.3 (10.2) 65.2 (10.6) 65.5 (9.9)
Men 85 (55.9) 88 (58.7) 87 (57.6)
Occupational group:
Professional, managerial, and
clerical
80 (52.6) 81 (54.0) 84 (55.6)
Skilled manual or manual 69 (45.4) 68 (45.3) 66 (43.7)
No occupation stated 3 (2.0) 1 (0.7) 1 (0.7)
Age (years) at leaving full time
education:
<17 109 (71.7) 114 (76.0) 121 (80.1)
17 or 18 20 (13.2) 14 (9.3) 13 (8.6)
>18 23 (15.1) 22 (14.7) 17 (11.3)
Cigarette consumption:
Never smoked 58 (38.2) 54 (36.2) 54 (35.8)
Former smoker 80 (52.6) 74 (49.7) 77 (51.0)
Current smoker 14 (9.2) 21 (14.1) 20 (13.2)
Duration of diabetes and treatment
Median (interquartile range)
duration (years) of diabetes
3(2-6) 3(2-7) 3(2-6)
Treatment:
Diet only 44 (28.9) 39 (26.0) 41 (27.2)
Monotherapy 57 (37.5) 58 (38.7) 58 (38.4)
Combined oral therapy 51 (33.6) 53 (35.3) 52 (34.4)
Presence of diabetes related
complications
32 (21.1) 32 (21.3) 39 (25.8)
Use of blood glucose meter:
Not using 104 (68.4) 110 (73.3) 102 (67.5)
Using once weekly or less 48 (31.6) 40 (26.7) 49 (32.5)
Physical and laboratory findings
Mean (SD) haemoglobin A1c (%) 7.49 (1.09) 7.41 (1.02) 7.53 (1.12)
Mean (SD) total cholesterol level
(mmol/l)
4.7 (1.1) 4.6 (1.1) 4.7 (1.1)
Mean (SD) blood pressure (mm
Hg):
Systolic 140 (18) 141 (17) 137 (18)
Diastolic 80 (10) 80 (10) 78 (10)
Mean (SD) body mass index 30.9 (6.1) 31.9 (6.2) 31.0 (5.3)
*No use of blood glucose meter.
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checked by the research nurses using a test aliquot at
baseline and at six months.
Data on adverse reactions or complicationswere col-
lected at each study visit, together with information on
the use of drugs.
Delivery of intervention
Training and support for the researchnurses delivering
the intervention was designed to ensure adherence to
the study protocol.15 The nurses were taught psycholo-
gical theory and trained in behaviour change techni-
ques and skills in delivering the intervention (six days
of case based training over five weeks). Intervention
protocols included scripts of the topics to be covered
to guide the nurses in talking to patients. Additional
measures to ensure adherence to the intervention pro-
tocols included self review of taped consultations by
the research nurses and external review by a sociolo-
gist. Prompts were also built into the patient diaries to
help patients adhere to their allocated intervention.
Statistical analysis
The trial was designed to have a 90% power to detect a
difference of 0.5% in HbA1c levels as the primary end
point at a two sided significance level of P<0.05. We
estimated the standard deviation of HbA1c levels to be
1.5% based on a previous trial of patients with type 2
diabetes,16 and assumed a 10% loss to follow-up. We
required a total of 630 patients to achieve the specified
statistical power. Subsequently we revised the esti-
mated standard deviation for HbA1c levels to 1.25%
when it became clear that it had been overestimated.
We retained a 10% dropout rate and 90% power and
revised the recruitment target to 450 patients.
We carried out a single intention to treat analysis of
the main trial end points at the end of the study using
analysis of covariance to compare mean levels of
HbA1c at follow-up between the three allocated
groups, with the baseline level of HbA1c as a covariate.
If no follow-up data were available we imputed values
by carrying forward the last available measurement.
We specified that in the event of a statistically signifi-
cant overall result, comparisons of the two self moni-
toring groups independently with the control group
would be carried out using t tests. Levels of HbA1c
over the course of the trial were compared between
groups using repeated measures analysis of variance.
We also estimated the intervention effect in prespeci-
fied subgroups defined at baseline as duration of dia-
betes (above or below median), current management
(oral hypoglycaemic drugs or dietary management
only), health status (above or below the median EQ-
5D score), and presence or absence of diabetes related
complications. We tested for effect modification using
analysis of covariance.
A Kaplan-Meier plot was used to explore adherence
to aminimal level of self monitoring, defined as at least
26 tests over threemonths (equivalent to two tests each
week); significance was assessed with a log rank test.
The mean numbers of tests by patients carrying out at
least 26 tests in each quarter are also reported, with
differences between the less intensive and more
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7.2
7.4
7.6
7.8
8.0
P=0.38
Control: no blood glucose meter
Less intensive self monitoring with blood glucose meter
More intensive self monitoring with blood glucose meter
Fig 2 | Change in HbA1c levels over 12 months’ follow-up of
patientswith non-insulin treated type 2 diabetes according to
randomisation group
Table 2 | Changes in haemoglobin A1c levels, weight, and bodymass index between baseline and
one year in patientswith non-insulin treated type2 diabetes, by randomisation group. Values
aremeans (standard deviations) unless statedotherwise
Variable
Control group*
(n=152)
Meter group, less
intensive self
monitoring
(n=150)
Meter group, more
intensive self
monitoring
(n=151)
P value for
difference between
groups†
HbA1c (%):
Baseline 7.49 (1.09) 7.41 (1.02) 7.53 (1.12) 0.12
Follow-up 7.49 (1.20) 7.28 (0.88) 7.36 (1.05)
Change −0.00 (1.02) −0.14 (0.82) −0.17 (0.73)
Systolic blood
pressure (mm Hg):
Baseline 140 (18) 141 (17) 137 (18) 0.77
Follow-up 136 (18) 137 (17 ) 134 (17)
Change −4 (14.) −3 (16 ) −3 (14 )
Diastolic blood
pressure (mm Hg):
Baseline 80 (10) 80 (10) 78 (10 ) 0.67
Follow-up 77 (10 ) 78 (10 ) 76 (10)
Change −3 (9 ) −2 (9 ) −2 (8)
Weight (kg):
Baseline 86.7 (18.9) 90.4 (18.9) 86.9 (16.4) 0.37
Follow-up 86.4 (19.4) 89.9 (19.0) 86.1 (15.7)
Change −0.3 (2.7) −0.5 (2.6) −0.8 (3.3)
Total cholesterol
level (mmol/l):
Baseline 4.73 (1.02) 4.64 (1.11) 4.67 (1.07) 0.010
Follow-up 4.56 (1.03) 4.42 (0.95) 4.28 (0.84)
Change −0.16 (0.84) −0.22 (0.93) −0.40 (0.90)
Ratio of total
cholesterol to high
density lipoprotein
cholesterol‡:
Baseline 4.33 (1.12) 4.40 (1.33) 4.48 (1.35) 0.013
Follow-up 4.18 (1.12) 4.11 (1.17) 4.02 (1.17)
Change −0.15 (0.72) −0.29 (0.86) −0.46 (0.91)
Body mass index:
Baseline 30.9 (6.1) 31.9 (6.2) 31.0 (5.3) 0.41
Follow-up 30.8 (6.3) 31.8 (6.3) 30.7 (5.0)
Change −0.1 (1.0) −0.2 (0.9) −0.3 (1.2)
Change is measured as one year follow-up minus baseline values.
*No use of blood glucose meter.
†Adjustment for baseline values.
‡Based on 414 participants with paired values (137/152, 136/150, 141/151).
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intensive intervention groups compared with a
repeated measures analysis of variance.
RESULTS
Between January 2003 and December 2005, 453
patients with non-insulin treated type 2 diabetes from
48 practices in Oxfordshire and South Yorkshire were
randomised to one of three interventions (fig 1): usual
care (n=152), less intensive self monitoring, using a
blood glucose meter and advice to contact doctor for
interpretation of the results (n=150), and more inten-
sive self monitoring, with a blood glucose meter and
training in interpreting the results (n=151). Themedian
(range) number of patients per practice recruited in 24
Oxfordshire practices was 9 (2-24) and in 24 South
Yorkshire practices was 8 (3-16).
Baseline personal and clinical characteristics were
well balanced between the groups (table 1). The med-
ian (interquartile) duration of diabetes was 3.0 years
(1.8-6.4 years), mean (SD) age was 65.7 (10.2) years,
and mean (SD) level of haemoglobin A1c was 7.5%
(1.1). Only 57 (12.6%) patients were lost to follow-up,
which did not differ between groups (fig 1). Measure-
ments for high density lipoprotein cholesterol levels
were not obtained for 39 patients at baseline. At fol-
low-up, HbA1c measurements were not collected for
two patients, blood pressure for five, cholesterol levels
for 10, and high density lipoprotein cholesterol levels
for 15.
Primary outcome
Table 2 shows the main results. At 12 months no dif-
ference was found in HbA1c levels between the groups
after adjustment for baseline HbA1c levels (P=0.12).
The mean difference in change in HbA1c levels from
baseline to 12 months between the control group and
less intensive intervention group (not adjusted for
baseline) was −0.14% (95% confidence interval
−0.35% to 0.07%) and between the control group and
more intensive intervention group was −0.17%
(−0.37% to 0.03%). Figure 2 shows the change in
HbA1c levels over the 12 months of follow-up, with
no evidence of differences in levels between groups
over the period of follow-up (P=0.38).
Secondary outcomes
Asignificant differencewas found in the change in total
cholesterol levels between the three groups (P=0.010).
The mean difference in change in total cholesterol
levels from baseline to 12 months between the control
group and less intensive intervention group (not
adjusted for baseline) was −0.06.mmol/l (−0.26 to
0.14) and between the control group and more inten-
sive intervention group was −0.23 (−0.43 to −0.04). No
differenceswere found in the other secondary outcome
measures (table 2). Within the prespecified subgroups
no significant interactions were found with allocated
group (table 3).
Hypoglycaemia
During the trial one or more grade 2 hypoglycaemic
episodes were experienced by 14 patients in the con-
trol group, 33 in the less intensive intervention group,
and 43 in the more intensive intervention group
(χ22=18.3, P<0.001). Only one patient in the control
group experienced a grade 3 hypoglycaemic episode.
Use of meter
Patients allocated to less intensive selfmonitoringwere
significantlymore likely to persist with use of themeter
than those allocated to more intensive self monitoring.
Ninety nine (67%) of those receiving the less intensive
intervention and 79 (52%) of those receiving the more
intensive intervention continued to use the meter at
least twice a week for the 12 months of the study
(P=0.012; fig 3). Among those who continued to use a
Table 3 | Changes in haemoglobin A1c levels (%) betweenbaseline and one year by subgroupof
patientswith non-insulin treated type 2 diabetes. Values aremeans (standard deviations)
Variable
Control group*
(n=152)
Meter group, less
intensive self
monitoring (n=150)
Meter group, more
intensive self
monitoring (n=151)
P value for
interaction†
Duration of diabetes‡
≤36 months: 0.82
Baseline 7.29 (1.02) 7.35 (1.02) 7.41 (1.03)
Follow-up 7.30 (1.24) 7.23 (0.93) 7.25 (1.01)
Change 0.01 (1.03) −0.12 (0.85) −0.16 (0.73)
>36 months:
Baseline 7.70 (1.13) 7.48 (1.02) 7.67 (1.20)
Follow-up 7.70 (1.11) 7.33 (0.84) 7.49 (1.08)
Change −0.01 (1.01) −0.15 (0.80) −0.18 (0.73)
Baseline therapy
Diet only: 0.90
Baseline 7.18 (0.98) 6.85 (0.66) 7.18 (1.11)
Follow-up 7.21 (1.05) 6.90 (0.70) 7.09 (0.94)
Change 0.03 (0.80) 0.04 (0.64) −0.09 (0.72)
Oral drug therapy:
Baseline 7.61 (1.11) 7.61 (1.05) 7.66 (1.10)
Follow-up 7.61 (1.24) 7.41 (0.91) 7.46 (1.07)
Change −0.01 (1.10) −0.20 (0.87) −0.20 (0.73)
Health status (EQ-5D)§:
Diabetes >36 months: 0.63
Baseline 7.38 (1.02) 7.30 (0.96) 7.57 (1.21)
Follow-up 7.46 (1.16) 7.22 (0.76) 7.43 (1.16)
Change 0.07 (0.99) −0.08 (0.84) −0.13 (0.77)
Diabetes ≤36 months:
Baseline 7.54 (1.16) 7.50 (1.09) 7.34 (0.80)
Follow-up 7.43 (1.22) 7.37 (1.04) 7.14 (0.78)
Change −0.11 (1.14) −0.13 (0.80) −0.20 (0.67)
Diabetes related complications
Absent: 0.86
Baseline 7.53 (1.11) 7.51 (1.09) 7.71 (1.19)
Follow-up 7.48 (1.16) 7.32 (0.92) 7.43 (1.13)
Change −0.05 (1.02) −0.19 (0.88) −0.28 (0.74)
Present:
Baseline 7.32 (1.02) 7.07 (0.63) 7.00 (0.64)
Follow-up 7.52 (1.34) 7.12 (0.73) 7.16 (0.73)
Change 0.20 (1.02) 0.05 (0.56) 0.16 (0.56)
*No use of blood glucose meter.
†After adjustment for baseline values.
‡Median 36 months.
§EQ-5D score 0.814. Paired data for EQ-5D score available for 384 patients.
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meter, the mean number of readings over 12 months
was significantly higher among patients receiving the
more intensive intervention compared with those
receiving the less intensive intervention (P=0.022;
fig 4). Eight patients in the control group started using
self monitoring of blood glucose.
Changes in hypoglycaemic and lipid lowering drugs
No differences were found between the groups in the
proportions of patients prescribed an increase in hypo-
glycaemic drugs between baseline and 12 months. In
the control group 45 (30%) patients had increased
drugs compared with 43 (29%) in the less intensive
intervention group and 48 (32%) in the more intensive
intervention group. One patient in the control group,
four in the less intensive intervention group, and five in
themore intensive intervention groupwere using insu-
lin therapy by 12 months. No differences were found
between groups in the proportions of patients where
hydroxymethyl glutaryl coenzymeA reductase inhibi-
tor (statin) treatment was increased or added to ther-
apy. Overall, 17 (11%) patients in the control group,
11 (7%) in the less intensive intervention group, and
19 (13%) in the more intensive intervention group
who were not taking a statin at baseline were taking a
statin by 12 months.
Further analyses
Later paperswill report on quality of life, cost effective-
ness, and subgroup and more detailed multivariate
analyses.
DISCUSSION
No significant improvement in glycaemic control was
found after 12months in patientswith non-insulin trea-
ted type 2 diabetes using self monitoring of blood glu-
cose levels when compared to those not self
monitoring. No evidence was found of a significantly
different impact of self monitoring on glycaemic con-
trol when comparing subgroups of patients defined by
duration of diabetes, therapy, diabetes related compli-
cations, andEQ-5D score. Also no evidencewas found
that more intensive compared with less intensivemon-
itoring led to differences in glycaemic control.
Strengths and weaknesses of the study
In this study patients were independently randomised,
with concealed allocation of measurement of the main
outcome and a low loss to follow-up. Participants were
drawn from awell defined sampling frame and the rea-
sons for exclusion were fully recorded. Recruitment
targets were revised after baseline data on haemoglo-
bin A1c levels in the first 245 randomised patients indi-
cated that the standard deviation had been
overestimated in the original power calculations.9 We
did not, however, change the proposed power or sig-
nificance levels. Participants’ diabetes was reasonably
well controlled and although most were not using a
meter a minority had had experience of their use.
Both these factors may have limited scope for further
improvement in glycaemic control. However, the par-
ticipants were representative of well controlled non-
insulin treated patients with type 2 diabetes in the com-
munity who are the target group for current recom-
mendations of up to twice daily self monitoring and
testing after meals.17 18
Designing a trial to evaluate self monitoring of blood
glucose levels is complex because it must include an
educational component on the use and interpretation
of testing for the intervention group,19 whereas advice
on improving self care must be offered to the compar-
ison group.3 We tackled these issues by providing a
common structure for interventions, incorporating
standardised good care in all three arms of the trial
within which nurses discussed issues of glycaemic con-
trol, assessed either byHbA1c levels or self monitoring
of blood glucose, and its role in setting andmonitoring
self care goals.9 The stepwise approach to the inter-
ventions across the three arms of the trial allowed
examination of what aspects of the intervention, if
any, were responsible for improved outcomes. Recent
consensus guidelines have based recommendations for
self monitoring of blood glucose levels on a theoretical
potential to better self manage glycaemic control.20 21
We incorporated self monitoring of blood glucose
into a framework that, based on psychological theory,
should have optimised its effect. Careful specification,
training, and monitoring of consultations ensured that
the allocated interventions were delivered as
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planned,22 although some patients in the less intensive
intervention group may themselves have adopted a
more intensivemonitoring approach. Despite an inter-
vention based on standards of best clinical practice and
underpinned by appropriate psychological theory, we
found no convincing evidence of an effect on glycae-
mic control.
Strengths and weaknesses in relation to other studies
Comparisons with early trials of blood glucose moni-
toring are of limited relevance because of their small
size, the large quantity of blood required to be read by
older meters, and the skill required for their use. How-
ever, more recent trials have been carried out with
meters utilising technologies that require smaller
amounts of blood and simplified procedures for test-
ing. Our findings support those of a recent small trial
using standardised counselling for both intervention
and control groups.The trial reported a non-significant
reduction in HbA1c levels of 0.2% in the intervention
group compared with the control group.23 Our find-
ings, however, conflict with the findings of two of the
largest trials of selfmonitoring of bloodglucose to date.
One of these trials reported a significant decrease in
HbA1c level of 0.3% in the intervention group com-
pared with the control group.24 However, over 30%
of those randomisedwere lost to follow-up andmissing
values were not imputed, which might lead to bias. In
addition, initial specific training in use of a blood glu-
cose meter was not matched by additional training for
the control group, although all patients received diet-
ary advice regardless of randomisation. A second trial
reported a reduction in HbA1c level of 0.46% in the
intervention group compared with the control group.
Standardised counselling supporting lifestyle modifi-
cationwas, however, only provided to the selfmonitor-
ing group.25 This type of educational support for self
management in itself has been estimated as improving
HbA1c levels by 0.26%.26
Meaning of the study
Fewer people in our trial allocated to more intensive
self monitoring compared with less intensive self mon-
itoring continued testing; previous studies have found
that trying to understand blood glucosemeasurements
may lead to frustration when results do not fall into a
pattern, or cease to be of interest when they are entirely
predictable.27 Patients with reasonably well controlled
diabetes do not need active encouragement to use a
meter. The increased recording of hypoglycaemia in
the selfmonitoring armsmaybe a result of an increased
awareness of low blood glucose levels from using the
meter rather than a true biochemical difference
between groups. Although no improvement in glycae-
mic control was observed, a small but significant
improvement was found in total cholesterol levels
with the self monitoring intervention. This finding is
consistent with an increased intensity of self manage-
ment in these groups, possibly mediated through
increased dietary adherence or through taking lipid
lowering drugs more regularly.
Unanswered questions and future research
Recent systematic reviews have estimated a benefit of
0.4% from self monitoring,2 and on this basis a pre-
vious study has estimated an incremental cost of
£4500 (€6650; $8880) to £15 515 per quality of life
year gained. Our estimates of the size of effect on
HbA1c levels suggest that it is probable that the pre-
vious study underestimated the cost per quality of life
year gained. A comprehensive economic evaluation
with cost effectiveness estimates will be detailed in a
future report.
Evidence of benefit from self monitoring of blood
glucose for other patient groups is stronger. Large trials
of management of patients with type 1 diabetes have
incorporated self monitoring of blood glucose as an
essential part of self management.28 29 Self monitoring
for insulin treated patients with type 2 diabetes is
accepted practice, although the evidence base requires
further work and optimisation of its use may be possi-
ble.However, routine selfmonitoring of blood glucose
for patients with reasonably well controlled non-insu-
lin treated type 2 diabetes seems to offer, at best, small
advantages; is not well accepted; and the cost, effort,
and time involved in the procedures may be better
directed to supporting other health related behaviours.
Current guidelines for the use of self monitoring of
blood glucose among patients with reasonably well
controlled non-insulin treated type 2 diabetes should
be reviewed.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Self monitoring of glucose for non-insulin treated patients with diabetes is costly but may
improve glycaemic control
Although some observational studies have suggested benefits, the results of randomised
trials have been inconclusive
WHAT THIS STUDY ADDS
It is not necessary to routinely recommend self monitoring of blood glucose in reasonably
well controlled patients with non-insulin treated type 2 diabetes
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